Ge Jia-Chen, Tao Ming, Li Lei, Ma Zhao-Lai, Jiang Bin, Yuan Chun-Hui, Wang Hang-Yan, Peng Ying, Xiu Dian-Rong
Department of General Surgery, Peking University Third Hospital, Beijing, People's Republic of China.
Department of General Surgery, Peking University Third Hospital, Beijing, People's Republic of China.
Pancreatology. 2021 May 7. doi: 10.1016/j.pan.2021.04.010.
Surgical resection remains the only potentially curative treatment for pancreatic ductal adenocarcinoma (PDAC). However, a number of patients get disease recurred in a short time post-operation. Few studies have focused on the predictors of different recurrence patterns of PDAC.
To try to establish and verify a nomogram to predict recurrence free survival (RFS) in PDAC patients, and to distinguish the risk factors of local recurrence first and distant metastasis first via competing risk model.
Patients who underwent radical pancreatectomy for PDAC in our center from 2010 to 2018 were reviewed retrospectively. Kaplan-Meier methods and multivariate Cox regression analyses were used to identify the clinicopathological predictors of recurrence post-operation. And then, a nomogram was constructed and validated. Competing risk regression model was used to compare the predictors between local recurrence group and distant metastasis group.
A total of 200 patients were included into the final analysis, and 153 patients got disease relapsed post-operation. CA19-9 level, vascular resection, tumor differentiation, lymph node ratio (LNR) and adjuvant chemotherapy were identified as independent risk factors for recurrence free survival (RFS) and incorporated into the nomogram. The C-index of the nomogram was 0.650. Competing risk model indicated that the status of lymph-node metastasis was significantly associated the patterns of first relapse.
Nomogram and competing risk model were constructed to quantify the risk of recurrence following surgery for PDAC. Our findings may be useful for predicting RFS and recurrence pattern in clinical work.
手术切除仍然是胰腺导管腺癌(PDAC)唯一可能治愈的治疗方法。然而,许多患者在术后短时间内疾病复发。很少有研究关注PDAC不同复发模式的预测因素。
试图建立并验证一种列线图,以预测PDAC患者的无复发生存期(RFS),并通过竞争风险模型区分局部复发先于远处转移的危险因素。
回顾性分析2010年至2018年在本中心接受根治性胰腺切除术治疗PDAC的患者。采用Kaplan-Meier方法和多变量Cox回归分析来确定术后复发的临床病理预测因素。然后,构建并验证列线图。使用竞争风险回归模型比较局部复发组和远处转移组之间的预测因素。
共有200例患者纳入最终分析,153例患者术后疾病复发。CA19-9水平、血管切除、肿瘤分化、淋巴结比率(LNR)和辅助化疗被确定为无复发生存期(RFS)的独立危险因素,并纳入列线图。列线图的C指数为0.650。竞争风险模型表明,淋巴结转移状态与首次复发模式显著相关。
构建了列线图和竞争风险模型来量化PDAC手术后的复发风险。我们的研究结果可能有助于在临床工作中预测RFS和复发模式。